Solvay extends Quintiles partnership
development contract with Quintiles for further five years.
Under the existing partnership the two firms have worked together since 2001, completing three Phase III clinical testing programs, moving two compounds from Phase II to Phase III and produced conclusive Phase II data that resulted in the termination of two other programs. "Using Quintiles' global infrastructure and experts we've advanced projects at a much faster rate than we could have achieved alone, and with greater flexibility," said Werner Cautreels, CEO of Solvay. "Over the next five years we aim to achieve even higher levels of value in terms of efficiency, speed and cost-savings." No other terms of the deal were released by the Belgian pharma firm, who specialises developing drugs for areas of unmet medical need in the fields of neuroscience, cardio-metabolic, influenza vaccines and gastroenterology.
